Wall Street analysts expect Avid Bioservices Inc. (NASDAQ: CDMO) to report revenues of $ 9.95 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for the revenue of Avid Bioservices. The highest sales estimate is $ 12.90 million and the lowest is $ 7.00 million. Avid Bioservices reported revenues of $ 27.08 million in the same quarter last year, indicating a negative year-on-year growth of 63.3%. The company is expected to report its next earnings results on Monday 10 September.
On average, analysts expect Avid Bioservices to report sales of $ 54.60 million for the current fiscal year, with estimates ranging from $ 54.20 million to $ 55.00 million. For the following year, analysts expect the company to report sales of $ 69.70 million per share, with estimates ranging from $ 67.40 million to $ 72.00 million. Zacks' sales calculations are an average based on a survey of selling research firms related to Avid Bioservices.
Avid Bioservices (NASDAQ: CDMO) has published its quarterly results for the last time on Monday, July 16th. The biopharmaceutical company reported $ 0.05 earnings per share (EPS) for the quarter, with consensus estimates of ($ 0.15) analysts being exceeded by $ 0.20. Avid Bioservices had a negative net margin of 40.68% and a negative return on equity of 58.67%. The company had revenues of $ 6.94 million during the quarter compared to the consensus estimate of $ 6.51 million.
CDMO has been the subject of a number of reports from research analysts. ValuEngine has upgraded Avid Bioservices shares from a "strong sell" rating to a "sell" rating in a report on Wednesday, May 2. Zacks Investment Research reduced Avid Bioservices' shares from a & # 39; hold & # 39; credit to a & # 39; sell & # 39; credit in a research report on Thursday, July 19. HC Wainwright repeated a "buy" rating and set a target price of $ 6.00 on Avid Bioservices shares in a research report on Tuesday, July 17. Finally, Janney Montgomery Scott started the coverage of Avid Bioservices shares in a research report on Monday 25 June. They set a "buy" classification and a target price of $ 10.00 for the company. One investment analyst has rated the shares with a sell rating, one has a hold rating and five have assigned a buy-rating to the company's shares. Avid Bioservices has an average rating of & # 39; Buy & # 39; and an average price target of $ 7.50.
NASDAQ CDMO traded $ 0.49 during trading hours on Wednesday and reached $ 6.24. 641,663 shares of the company were exchanged, compared with the average volume of 295,261. Avid Bioservices has a 1-year low of $ 2.24 and a 1-year high of $ 6.57. The company has a market capitalization of $ 325.30 million, a PE ratio of -12.48 and a beta of 2.19.
A number of large investors have recently adjusted their participations in CDMO. BlackRock Inc. strengthened its position in Avid Bioservices by 329.6% during the second quarter. BlackRock Inc. now holds 3,261,288 shares of the biopharmaceutical company's share of $ 12,784,000 after the purchase of an additional 2,502,164 shares during the period. Bandera Partners LLC acquired a new position in Avid Bioservices in the first quarter of approximately $ 2,984,000. CVI Holdings LLC acquired a new position in Avid Bioservices in the first quarter of approximately $ 1,729,000. Schwartz Investment Counsel Inc. purchased a new position in Avid Bioservices in the first quarter of approximately $ 1,387,000. Finally, Wells Fargo & Company MN acquired a new position in Avid Bioservices in the first quarter of approximately $ 644,000. Hedge funds and other institutional investors hold 23.93% of the company's shares.
About Avid Bioservices
Avid Bioservices, Inc. operates as a contract development and production organization that focuses on the development and cGMP production of biopharmaceutical products derived from mammalian cell culture. It offers a range of process development and cGMP clinical and commercial production services for the biotechnology and biopharmaceutical industry.
Recommended story: Understand analyst recommendations
Receive a free copy of the Zacks research report on Avid Bioservices (CDMO)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive daily news and ratings for Avid Bioservices – Enter your email address below to receive a concise, daily summary of the latest news and reviews from analysts for Avid Bioservices and related companies with the FREE daily email newsletter from MarketBeat.com.